Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
XL 184 is a potent VEGFR inhibitor (IC50 = 0.035 nM); also inhibits c-Met, KIT, RET, FLT4, AXL, FLT3, FLT1 and Tie2 (IC50 values are 1.3, 4.6, 5.2, 6, 7, 11.3, 12 and 14.3 nM, respectively). Induces intratumoral hypoxia and apoptosis. Reduces tumor invasion and metastasis in vivo. Antiangiogenic.
XL 184 is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
|Storage||Store at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
The following data is based on the product molecular weight 501.51. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.99 mL||9.97 mL||19.94 mL|
|5 mM||0.4 mL||1.99 mL||3.99 mL|
|10 mM||0.2 mL||1 mL||1.99 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
References are publications that support the biological activity of the product.
You et al (2012) VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 71 4758 PMID: 21613405
Yakes et al (2011) Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol.Cancer Ther. 10 2298 PMID: 21926191
If you know of a relevant reference for XL 184, please let us know.
Keywords: XL 184, XL 184 supplier, Potent, VEGFR, inhibitors, inhibits, HGFR, HGF, receptor, vascular, endothelial, growth, factors, receptor,, tyrosine, kinases, RTKs, c-Met, KIT, FLT4, AXL, FLT3, FLT1, Tie2, apoptosis, metastasis, antiangiogenics, angiogenesis, antitumor, antitumour, XL184, Cabozantinib, BMS, 907351, MET, Receptors, Other, 5422, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for XL 184 include:
Martín-Segura et al (2019) Aging Increases Hippocampal DUSP2 by a Membrane Cholesterol Loss-Mediated RTK/p38MAPK Activation Mechanism. Front Neurol 10 675 PMID: 31293510
Do you know of a great paper that uses XL 184 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review XL 184 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.